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Patch Closure of Muscular Ventricular Septal
Defects With a New Hybrid Therapy in a Pig Model
Rainer Kozlik-Feldmann, MD,* Nora Lang, MD,* Regine Aumann, MD,* Anja Lehner, MS,*
Darius Rassoulian, MD,† Ralf Sodian, MD, PHD,† Christoph Schmitz, MD, PHD,†
Martin Hinterseer, MD,‡ Rabea Hinkel, MD, PHD,‡ Eckart Thein, MD,§ Franz Freudenthal, MD,
Nikolay V. Vasylev, MD,¶ Pedro J. del Nido, MD,¶ Heinrich Netz, MD, PHD*
Munich, Germany; La Paz, Bolivia; and Boston, Massachusetts
Objectives We evaluated a novel technique for hybrid patch closure of muscular ventricular septal defects (mVSDs) without
cardiopulmonary bypass (CPB) in a pig model.
Background So far, surgical and interventional therapies for mVSDs have been associated with significant morbidity, espe-
cially in newborns and infants. Thus, it is essential to develop new techniques. Hybrid therapy is an innovative
approach for mVSDs that combines the advantages of surgical and interventional techniques.
Methods Six pigs underwent left anterolateral thoracotomy to expose the left ventricle (LV). The mVSDs were created un-
der echocardiographic guidance with a 7.5-mm sharp punch instrument that was forwarded via an LV incision. A
special designed patch system composed of a patch with a Nitinol frame was passed across the carotid artery
into the LV and positioned in front of the mVSD. An instrument resembling a stapler was introduced across the
LV wall on the beating heart without use of CPB. The patch was fixed with Nitinol anchors on the septum under
echocardiographic and fluoroscopic guidance. Finally, the Nitinol frame was detached from the patch.
Results The locations of the defects were apical (n  1), midmuscular (n  3), and anterior muscular (n  2). Closure of
the mVSD was successful in 5 of 6 animals confirmed by echocardiography, hemodynamic measurements, and
explantation of the heart. Animals were hemodynamically stable throughout the experiment.
Conclusions Here, we present a novel technique for hybrid closure of mVSDs without use of CPB. Further development of the
patch system is necessary to assess applicability in humans, especially for the target group of newborns and
infants. (J Am Coll Cardiol 2008;51:1597–603) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.10.068t
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centricular septal defects (VSDs) are one of the most
ommon congenital cardiac defects and account for approx-
mately 30% of all congenital heart diseases (1). They are
lassified according to their location in the septum (2).
uscular ventricular septal defects (mVSDs) account for
pproximately 10% to 15% of all VSDs (3).
Until now, therapy for mVSDs beyond the moderator
and has been challenging, especially in newborns and
nfants, and is associated with increased morbidity and
ortality. Both surgical and interventional approaches have
rom the Departments of *Pediatric Cardiology, †Cardiac Surgery, and ‡Cardiology,
niversity Hospital Grosshadern, Munich, Germany; §Institute of Surgical Research,
udwig-Maximilians-University, Munich, Germany; Department of Pediatric Car-
iology, Kardiozentrum, La Paz, Bolivia; and the ¶Department of Cardiac Surgery,
hildren’s Hospital Boston and Harvard Medical School, Boston, Massachusetts.
his work was supported by Elterninitiative Großhadern e.V., and Heart for Heart
oundation, Munich, Germany. Philips Medical Systems, GmbH, provided the
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Manuscript received July 26, 2007; revised manuscript received October 10, 2007,
ccepted October 23, 2007.heir limitations. Surgical repair of these defects beyond the
oderator band might frequently require left ventriculot-
my or the division of multiple important right-sided
uscle bands. These procedures are often associated with
ignificant morbidity and mortality (4). Moreover, surgery is
ssociated with prolonged hospital admission, a scar, and
atient discomfort (5). Furthermore, surgery requires the
se of cardiopulmonary bypass (CPB), which might be
ssociated with various adverse effects, such as impaired
eurologic development (6,7) or systemic inflammatory
esponse syndrome (SIRS) (8).
Recently there has been an increase in the use of alternative
nterventional strategies. These interventions are limited by
oor vascular access and low patient weight, especially in young
nfants (9–11). Currently, the devices used in these interven-
ions are still at an investigational stage. In addition, there are
everal reports about significant arrhythmias, hemodynamic
ompromises, valve injuries, or incomplete closure (12,13).
Hybrid cardiac surgery, a combination of interventional
nd surgical techniques, has been demonstrated as a new,
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Patch Closure of VSDs April 22, 2008:1597–603innovative approach for therapy
of mVSDs, because it reduces
operation times, complexity, op-
erative trauma, and avoids use of
CPB (10,14). Several authors re-
ported off-pump closure of
mVSDs with an Amplatzer de-
vice via a perventricular ap-
proach. Advantages over open
repair included avoidance of
trans-section of the moderator
band or other right ventricular
muscle bundles without limita-
tions of vascular access or pa-
tient weight (14). Nevertheless,
authors also reported valve in-
juries, device embolization into
the aorta, and rhythm distur-
bances (10).
Thus, new therapeutic strate-
gies have to be developed. Here,
we present a new method for
losure of mVSDs with a patch delivery device and mini
itinol anchors in a hybrid technique.
ethods
nimals. We used 6 German Landrace piglets of either
ender (20 to 30 kg), which were purchased from the farm
f the university (Oberschleissheim, Germany). The exper-
mental protocol was approved by the local Governmental
ommission on the Care and Use of Animals. The animals
eceived care in compliance with the Guide for the Care and
se of Labarotory Animals. All experiments were per-
ormed in the laboratory of Surgical Research, Walter-
rendel-Center for Experimental Medicine, at the Ludwig-
aximilians-University of Munich.
nesthesia. First, the piglets were fasted overnight and
re-medicated with an intramuscular injection of 500 mg
etamine, 10 mg/kg body weight azaperone, and 0.5 mg
tropine. After cannulating an ear vein, midazolame (0.1
g/kg body weight intravenously) was administered. The
nimals were intubated with a 6.5-F (Charriere scale) tube
nd ventilated with a inspiratory oxygen concentration of
0%. Anesthesia was induced and maintained with propofol
induction 1.5 to 2 mg/kg body weight, maintenance 10
g/kg body weight/h) and fentanyl (induction 0.02 mg/kg
ody weight, maintenance 0.045 mg/kg body weight/h).
he respiratory rate and tidal volume were adjusted to keep
he arterial partial pressure of carbon dioxide (pCO2)
etween 35 and 45 mm Hg. Arterial blood samples were
btained for analyses of partial pressure of oxygen (pO2),
artial pressure of carbon dioxide in the arterial blood
PaCO2), and pH. Before performing thoracotomy, muscle
Abbreviations
and Acronyms
CPB  cardiopulmonary
bypass
CVP  central venous
pressure
LV  left
ventricle/ventricular
mVSD  muscular
ventricular septal defect
PAB  pulmonary artery
banding
PCWP  pulmonary
capillary wedge pressure
RVP  right ventricular
pressure
SIRS  systemic
inflammatory response
syndrome
VSD  ventricular septal
defectaralysis was induced with pancuronium bromide, 0.1g/kg body weight intravenously; additional doses were
dministered when necessary.
Intravenous fluids (Ringer solution) were given at a rate
f 10 ml/kg body weight/h and increased when necessary.
ydroxy ethyl starch 6% was given in case of relevant blood
oss. Oxygenation, electrocardiogram, and temperature
ere also monitored and recorded continuously. Amioda-
one (20 mg/kg body weight/d) and magnesium were
dministered throughout the procedure to prevent ventric-
lar arrhythmias.
evice and stapler. The patch delivery device consisted of
self-expanding frame made of a 0.25-mm  0.75-mm
itinol wire (wire 1) covered by a polyethylene tube (1.5
m in diameter) and a grip. A 0.1-mm polyester patch was
ppropriately trimmed and then attached to the Nitinol
rame by a 0.1-mm Nitinol wire (wire 2) (Fig. 1, upper
anel) (15). A custom-designed stapler was used to fix the
atch on the septum with mini-anchors made of Nitinol
Fig. 1, lower panel).
Figure 1 Basic Construction of the Patch Delivery
Device and the Custom-Designed Stapler
The upper panel shows the polyester patch and the patch delivery device (B).
(A and C) Enlargement of B, whereas A shows the back and C the front. The
lower panel presents the custom-designed stapler. (E) Enlargement of the
front of the custom-designed stapler and a mini Nitinol anchor. (F) Demon-
strates how the mini Nitinol anchor is fixated in the plier contained in the
stapler.
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April 22, 2008:1597–603 Patch Closure of VSDsmaging. For imaging, 2-dimensional (2D) and 3-
imensional (3D) echocardiography were used. For 2D echo-
ardiography (Sonos 5500, Philips Healthcare, Andover,
assachusetts), a 5-MHz transesophageal echocardio-
raphic probe was placed behind the beating heart via an
ncision of the 6th intercostal space. The 3D echocardiog-
aphy was performed epicardially by using the X7-2 matrix
ransducer of the IE33 Ultrasound System (Philips Health-
are). Additionally, closure of the mVSD was performed
nder fluoroscopic guidance.
urgical preparation. All animals were shaved for thora-
otomy and neck dissection on the right side. Afterwards,
he right-sided external carotid artery and the jugular vein
ere exposed. The external carotid artery was cannulated
ith a 9-F and the jugular vein with an 11-F introducer
heath. Arterial pressure and central venous pressure (CVP)
ere measured continuously.
Animals were placed in dorsolateral recumbency with the
eft side upward. A left fourth intercostal thoracotomy was
erformed, and the heart was exposed by incising the
ericardium. The following steps were performed without
PB. Two 4-0 polypropylene purse-string sutures on the
V wall were applied for instrument insertion.
reation of mVSDs. Creation of mVSDs was achieved
nder 2D and 3D echocardiographic guidance with a special
esigned punch instrument via an LV incision (7.5 mm)
Fig. 2). Successful creation of an mVSD was confirmed by
chocardiography and oxymetric measurement of the shunt
olume by the Fick method.
VSD closure. A 7-F introducer sheath shortened to 2 cm
as inserted through the incision in the LV wall, which was
lso used for creation of the mVSDs in order to minimize
V trauma during the closing procedure. Contrast medium
as applied to detect the mVSD in fluoroscopy.
The patch delivery device was inserted into a custom-
esigned, 30-cm-long 7-F sheath. It was forwarded over a
-F pigtail catheter via the 9-F introducer sheath across the
arotid artery into the left ventricle (LV). The patch wasd
Figure 2 The Special Designed Punch Instrumenteployed and positioned over the defect under fluoroscopic
nd echocardiographic guidance.
The custom-designed stapler was introduced through the
hortened 7-F sheath inside the lateral LV wall. Then, the
atch was fixed with 8 to 10 Nitinol mini anchors (Fig. 1)
nder echocardiographic and fluoroscopic guidance. After
ecured fixation the Nitinol frame was detached from the
olyester patch by releasing the sutures (pulling the Nitinol
ire 2) (Fig. 1) and was drawn back into the long 7-F
heath.
Finally, animals were killed by an intracardial injection of
0 mval potassium chloride.
Autopsy of the hearts revealed the location of the mVSD
s well as the position and fixation of the patch.
easurements and echocardiography. Arterial blood
amples were obtained continuously to control appropriate
entilation. Heart rate (HR), arterial pressure, and CVP
ere measured and recorded. The following hemodynamic
arameters were obtained as baseline before performing
horacotomy: CVP, pulmonary arterial pressure, and pul-
onary capillary wedge pressure (PCWP). Echocardiogra-
hy was performed to exclude congenital defects such as
eptal defects and valve insufficiencies.
After creating the shunt the same hemodynamic param-
ters as described previously were obtained. Blood samples
ere taken to measure the shunt volume. Echocardiography
as used to assess the diameter of the created VSD.
After closure the residual shunt volume was measured by
btaining the required hemodynamic parameters. Addition-
lly, echocardiography was performed to detect potentially
xisting residual shunts and valve insufficiencies.
tatistical analysis. Values are presented as mean  SD.
or comparison of paired observations, the paired t-test was
sed without correction for multiple comparisons. A p value
0.05 was considered statistically significant.
esults
reation of mVSDs. Echocardiography and hemody-
amic measurements before the procedure excluded valve
nsufficiencies and cardiac defects as well as relevant shunt-
ng in all animals. Creation of an mVSD under echocardio-
raphic guidance was successful in all animals (n 6) (Fig. 3).
he mean size of the created mVSDs was 6.0  0.7 mm, as
etermined by 2D echocardiography (Table 1, Fig. 3).
uccessful creation of the defects was also confirmed by 3D
olor Doppler echocardiography (Fig. 3). Shunt volumes
anged from 10.2% to 41.3%, mean 20.1%. The defects
ere located in the apical (n 1), midmuscular (n 3), and
nterior (n  2) septum revealed by explantation of the
eart at the end of the experiment (Table 1). Animal 6
eeded dopamine in a dose of 3 g/kg/min after creation of
he defect, because the LV showed a volume overload.
entricular septal defect closure. Figure 4 demonstrates
he main principle of our hybrid therapy. The patch delivery
evice was inserted into the long 7-F introducer sheath and
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Patch Closure of VSDs April 22, 2008:1597–603orwarded across the carotid artery into the LV. Because the
atch delivery device consists of Nitinol, the patch expanded
asily to its original form after deploying through the end of
he sheath. Maneuvering of the patch in the LV and
ositioning in front of the defect was performed without any
ifficulties.
Successful closure of the mVSD was completed under
chocardiographic and fluoroscopic guidance in 5 of 6 animals
Fig. 5). The absence of residual shunts in these animals was
onfirmed by 2D and 3D color Doppler echocardiography. No
eft to right shunt could be detected after closure in 5 of 6
nimals. The patch in the sixth animal was positioned too
edially. Echocardiography and hemodynamic measurements
howed significant residual shunting. None of the animals
eeded catecholamines at the end of the procedure. However,
ll animals showed mild tricuspid and mitral valve insufficiency.
dditionally, 1 animal had mild to moderate aortic valve
nsufficiency.
xamination of the explanted hearts. Examination of the
xplanted hearts revealed substantial mVSDs. The diam-
ters of the mVSDs were in accordance with the echo-
Figure 3 A Representative mVSD
A midmuscular ventricular septal defect (mVSD) is shown
in 2-dimensional echocardiography. LV  left ventricle; RV  right ventricle.
elevant Data About Animals 1 to 6
Table 1 Relevant Data About Animals 1 to 6
Animals
VSD
(mm) VSD Location
Need of
Catecholamines
Successful
Implantation
1 6.0 Anterior muscular No Yes
2 6.0 Midmuscular No Yes
3 5.1 Anterior muscular No Yes
4 6.3 Midmuscular No Yes
5 6.7 Midmuscular No No
6 6.0 Apical Dopamine (3 g/kg/min
after creation of the
mVSD and during
closure)
YestVSD  muscular ventricular septal defect; VSD  ventricular septal defect.ardiographic measurements in all investigated hearts
Table 2).
Furthermore, appropriate position and fixation of the
atch could be confirmed in 5 of 6 animals (Fig. 6). In the
ixth animal the patch did not cover the defect completely,
nd a residual defect of 3 mm remained.
No structures of the mitral and tricuspid valve apparatus
ere injured during patch closure. No damage was seen at
he side of the aortic valve even in the animal with the mild
o moderate aortic insufficiency.
emodynamic measurements. Pigs were hemodynami-
ally stable throughout the whole experiment (Fig. 7).
opamine was administered in only 1 animal (Table 1). All
emodynamic data did not show any significant difference.
lthough not statistically significant, pulmonary arterial
ressure and PCWP measurements showed a tendency to
ncrease after creation of the mVSD. At the end of the patch
losure there was no additional increase of these values.
iscussion
e present a new technique for hybrid closure of mVSDs
ithout using CPB. In general, hybrid therapy, a combina-
ion of interventional and surgical techniques, seems to be a
ew innovative approach for therapy of mVSDs (10). So far,
oth surgical and interventional therapies for mVSDs have
Figure 4 Demonstration of the Main
Principle of Our New Hybrid Therapy Ex Vivo
(A) The patch delivery device is put on a piece of muscular septum. (B and C)
Fixation of a mini Nitinol anchor on the muscular septum with the custom-
designed stapler. (D) Fixation of the patch with 7 mini Nitinol anchors.
(E) After releasing the sutures the Nitinol frame detaches from the patch. (F)
The patch remains with the mini Nitinol anchors in the muscular septum.heir limitations.
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April 22, 2008:1597–603 Patch Closure of VSDsSurgical repair of these defects continues to represent a
ignificant challenge. Incidence of residual mVSDs still
emains high after surgery (4). Reoperation rates up to 10%
ave been reported (16). Owing to technical difficulties, for
any mVSDs below the moderator band pulmonary artery
anding (PAB) is the preferred therapy in order to postpone
orrective surgery. Interventional therapies are often limited
y poor vascular access, low patient weight, and rhythm
isturbances (10).
First hybrid procedures for other cardiac defects have
lready been described in the 1980s, such as intraoperative
alloon occlusion of the Blalock Taussig shunt and intra-
perative balloon dilation of critical aortic stenosis in neo-
ates and infants (17,18). Newer hybrid procedures are
ulmonary valve replacement or duct stenting combined
ith bilateral PAB as an alternative first-step approach for
hildren with hypoplastic left heart syndrome (19,20).
ecently, several authors reported off-pump closure of
VSD with an Amplatzer device via a perventricular
pproach (10,21). Besides the advantages, they also had to
Figure 5 Implantation and Fixation of the Patch
(A) Fluroroscopic images before (left panel) and after (right panel) pulling the
Nitinol wire 2. (B) Three-dimensional (3D) echocardiography of the patch and
the patch delivery device put on the muscular septum. (C) Three-dimensional
echocardiography of the patch and the mini Nitinol anchors after the patch
delivery device was drawn back into the 7-F sheath.
emodynamic Data Throughout the Experiment
Table 2 Hemodynamic Data Throughout the Experiment
Parameter Baseline
After Creation of
the mVSD
After Closure of
the mVSD
MAP (mm Hg) 80.0 13.3 74.5 20.8 71.5 13.9
CVP (mm Hg) 8.0 2.7 9.6 4.6 8.6 3.7
Systolic PAP (mm Hg) 27.3 4.2 33.83 6.1 34.5 9.4
PCWP (mm Hg) 7.75 1.2 15.2 4.7 14.0 3.2VP  central venous pressure; MAP  mean arterial pressure; mVSD  muscular ventricular
eptal defect; PAP  pulmonary arterial pressure; PCWP  pulmonary capillary wedge pressure.eal with a set of complications, such as valve injuries,
evice embolization into the aorta, and rhythm disturbances
10). But the authors believe children will profit from
mproving hybrid therapy, especially patients with complex
efects beyond the moderator band.
Because previous therapeutic strategies for mVSD closure
ave had their limitations, we performed a pilot study to
Figure 6 Explantated Heart of Animal 2
Appropiate position and fixation of the patch. The ellipse
points to the location of the muscular ventricular septal defect.
Figure 7 Hemodynamic Stability During the Whole Experiment
Mean arterial pressure (red circles) and central venous pressure (black cir-
cles) during the course of the experiment. Application of catecholamines was
not necessary. 1  skin cut; 2  creation of the muscular ventricular septal
defect; 3  implantation of the patch; 4  fixation of the patch.
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Patch Closure of VSDs April 22, 2008:1597–603valuate a new hybrid therapy for mVSD closure. The
onstruction of the patch delivery system and the custom-
esigned stapler have been described recently (15). In
rinciple, a patch with a Nitinol frame was delivered across
he carotid artery into the LV and positioned over the
efect. Afterwards, it was fixed with a custom-designed
tapler. Finally, the Nitinol frame was detached from the
atch and could be easily drawn back into a 7-F sheath, so
hat only the patch with the mini Nitinol anchors remained
n the muscular septum. The mVSDs were successfully
losed in 5 of 6 animals without a residual shunt.
Our method combines surgical and interventional advan-
ages, because it can be performed without the use of CPB.
irst of all, the use of an LV approach might have some
dvantages over repair from the right ventricular side. Many
VSDs are very difficult to detect from the right ventricular
ide, because of muscular trabeculations. The margins of an
VSD are much easier to define from the LV side, owing
o the smooth surface of the septum. Furthermore, the
ressure gradient between left and right ventricular side
upports the patch alignment to the muscular septum. But
ntil now, LV approaches were rarely undertaken because of
he risk of development of impaired LV function. In our
roposed hybrid therapy, a minimal LV incision, approxi-
ately 2 mm, has to be made for fixation of the patch by the
ustom-designed stapler. Thus, the approach proposed in
his report might offer the benefits of closure of a VSD
hrough the LV without the complications of a large LV
ncision. We believe that the risk of development of LV
ysfunction will be significantly reduced.
Combination of echocardiography and fluoroscopy in our
ew technique is reasonable, because the exposure to radi-
tion can be reduced. Recently, several therapeutic strategies
roposed implantation of the Amplatzer device as a hybrid
echnique (9,15). The Amplatzer device is quite stiff and
nflexible. There is a potential risk of damage for adjacent
natomical structures, especially valves and the conduction
ystem (9,22,23). Thus, we believe implantation of a patch
n hybrid technique is an innovative approach, because a
atch shows a high flexibility and has a lower risk of hurting
djacent anatomical structures.
In the future, a chronic setting of these experiments is
eeded to evaluate how the patch will integrate with the
yocardium and whether LV dysfunction or pulmonary
ypertension develops. In this set of experiments, PCWP
oubled at the end of the experiment after VSD procedure.
his effect was not statistically significant, but we believe
his is due to the small sample size. This indicates stress to
he ventricles due to the VSD creation. After the patch
mplantation no additional increase of the PCWP was seen.
future chronic investigation must address whether there is
considerable, long-term depression of the myocardium.
urthermore, it is important to observe whether the valve
nsufficiencies we have seen at the end of the procedure will
ccelerate, level off, or deteriorate. Insufficiencies of the
trioventricular valves were mostly seen after mVSD cre- ition. An additional negative effect due to the implantation
rocedure could not be seen. The mild aortic valve insuffi-
iency observed in 1 animal is probably related to the
xtension of the valve by the implantation sheath. A damage
f the valve itself could not be seen in the autopsy.
Some might argue that we used the external carotid artery
s peripheral vascular access instead of the femoral artery,
hich would be the typical access in humans. We believe
hat the implantation can also be done from the femoral
rtery. Thus, further experiments are needed to evaluate the
easibility of patch implantation across the femoral artery.
tudy limitations. In our study, we used animals weighing
0 to 30 kg. Large arterial and venous sheaths were
equired. For this first feasibility study we decided to use
arge patches, carrier systems, anchors, and application
ystems in order to evaluate a general applicability of this
ystem. We plan to modify this system to 5-F in order to
ake it usable in smaller piglets weighing approximately 5
o 10 kg. We are aware that only a minimized working
ystem will allow us to treat newborns and avoid a
rimary PAB.
Shunt measurements sometimes were unexpectedly small,
lthough echocardiographic assessment of the mVSD and
xplantation of the heart revealed moderate to large VSDs.
e believe that swelling of the surrounding area of the
reated mVSD could be responsible for quite small shunt
olumes. Nevertheless, explantation of the heart revealed
hat we created substantial defects. Thus, myocardial swell-
ng is a problem of this acute animal model. Conversely, we
elieve that creation of bigger mVSDs could have resulted
n the death of the animal, because an acute creation of
SDs is associated with a large hemodynamic compromise.
owever, the explanted heart revealed that the mVSDs
ere covered by the patch completely in 5 of 6 animals.
herefore, without swelling, closure of the defects would
ave also been successful.
Appropriate imaging was essential for this study. To date,
mplantation is mainly done under guidance of fluoroscopy
nd 2D transesophageal echocardiography. Epicardial 3D
chocardiography might be theoretically beneficial, because
n on-face view of the VSD and patch can be produced.
owever, simultaneous epicardial echocardiography and
xation of the patch is challenging at this time. Therefore,
maging has to be developed further. We believe that a
D transesothat a 3Dphageal probe placed behind the
eart will improve implantation significantly. There is a
otential risk of embolization of the Nitinol anchors.
his might be dangerous for patients. In this series, of 49
itinol anchors, 3 embolizations occurred. For this
eason, further development of the application device is a
ajor issue and the staplers will be modified. We plan to
ncorporate a stop mechanism before the anchors are
eleased. Besides, we believe angled staplers will facilitate
mplantation significantly.
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April 22, 2008:1597–603 Patch Closure of VSDsonclusions
n conclusion, we present a novel hybrid technique for
VSD closure without using CPB and with a minimal LV
ncision, which might be an alternative therapeutic option
or newborns instead of PAB. However, further evaluation
nd development of the patch delivery device and the
ustom-designed stapler is necessary to assess their applica-
ility in humans, especially in newborns and infants.
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